Latest News?

Cardiol Therapeutics announced on January 17, 2023, that the first patient has been enrolled in a Phase II study evaluating CardiolRx™ for the treatment of recurrent pericarditis. The study aims to assess the drug's tolerance, safety, and efficacy, with a total of 25 patients expected to be enrolled at clinical centers in the United States.

Answer last refreshed: 2026-08-18